A. Vallejo

TL;DR: Systemic markers of innate and adaptive immunity in a cohort of HIV-infected individuals on successful antiretroviral therapy without comorbidities and in healthy non-HIV- infected subjects are determined.

TL;DR: Molecular analyses were performed on 215 DNA samples by PCR amplification using HTLV‐I and ‐II gag, pol, env, pX and LTR specific primers, and Reverse transcriptase (RT) assay was performed in 26 cases using an RT‐PCR‐based method of high sensitivity.

TL;DR: Genotypic resistance to antiretroviral drugs was examined in 684 individuals attending 18 outpatient clinics distributed across Spain in June 2000, finding the prevalence of resistance to nucleosides has declined significantly and resistance among naive chronic HIV carriers has increased.

TL;DR: Baseline thymic volume was associated independently with the magnitude of short‐ and long‐term recovery of CD4+ T cells after HAART, despite the patients’ viral phenotype, which could have important clinical implications not only in HIV‐infected patients, but also in other scenarios of T cell depletion such as bone marrow transplantation and chemotherapy.

TL;DR: The findings suggest that drug resistance mutations are very prevalent among subjects who have experienced several treatment failures, and facilitating the arrival of compounds belonging to new drug classes should be considered a priority.